诺思格(301333) - 2024 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2024 reached ¥182,933,748.78, an increase of 12.42% year-over-year, while year-to-date revenue totaled ¥561,924,953.41, up 7.10% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥25,906,667.14, a decrease of 35.04% year-over-year, with year-to-date net profit at ¥84,417,173.32, down 32.93%[2] - Basic earnings per share for Q3 2024 was ¥0.27, reflecting a decline of 35.71% year-over-year, while year-to-date basic earnings per share was ¥0.88, down 32.82%[2] - Total operating revenue for Q3 2024 reached ¥561,924,953.41, an increase of 7.6% compared to ¥524,666,803.13 in the same period last year[24] - Net profit for Q3 2024 was ¥85,896,155.95, a decrease of 31.9% from ¥126,307,007.23 in Q3 2023[25] - The total comprehensive income attributable to the parent company was CNY 84.10 million, a decrease from CNY 125.73 million in the previous year, representing a decline of about 33.1%[26] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥2,298,881,931.34, representing a 10.85% increase from the end of the previous year[2] - The company's total assets increased to ¥2,298,881,931.34, compared to ¥2,073,816,068.79 at the end of the previous year, marking a growth of 10.8%[24] - Current liabilities rose to ¥444,746,001.68, up from ¥314,357,004.32, representing an increase of 41.4%[24] - The company’s total equity attributable to shareholders increased by 2.12% year-over-year, reaching ¥1,785,493,360.90[2] - The total equity attributable to shareholders reached ¥1,785,493,360.90, up from ¥1,748,411,556.50, reflecting an increase of 2.1%[24] Cash Flow - The company reported a net cash flow from operating activities of ¥105,405,875.78 year-to-date, which is a decrease of 18.40% compared to the same period last year[2] - The net cash flow from investing activities decreased by 42.03% to -380,303,828.54 RMB compared to the previous year, primarily due to reduced cash management product investments[11] - The net cash flow from financing activities increased by 153.07% to -37,999,306.16 RMB, mainly due to increased dividend payments and bank acceptance bill guarantees[11] - The net increase in cash and cash equivalents was -314,278,679.33 RMB, down 41.75% year-on-year, attributed to decreased cash management product investments[11] - The cash and cash equivalents at the end of the period were CNY 677.20 million, down from CNY 981.64 million at the end of the previous year, indicating a decrease of approximately 30.9%[29] Shareholder Information - The total number of common shareholders at the end of the reporting period was 5,836, with the largest shareholder, ACE UNION HOLDING LIMITED, holding 28.68% of shares[12] - The second-largest shareholder, Ningbo Kaihong Venture Investment Partnership, held 12.23% of shares, totaling 11,736,000 shares[12] - The company’s repurchase account held 1,442,000 unrestricted shares, accounting for 1.50% of the total share capital at the end of the reporting period[14] - As of September 30, 2024, the company has repurchased a total of 1,442,000 shares, accounting for 1.50% of the total share capital of 96,000,000 shares, with a total transaction amount of 56,062,734.00 RMB[19] - The company plans to repurchase shares with a total amount not less than 50 million RMB and not exceeding 80 million RMB, with a repurchase price capped at 57.80 RMB per share[18] Expenses and Costs - Total operating costs amounted to ¥479,667,281.05, up from ¥409,051,992.42, reflecting a year-over-year increase of 17.2%[25] - Management expenses for the year-to-date period reached ¥85,287,977.23, an increase of 86.91% year-over-year, primarily due to stock incentive plan amortization[10] - Research and development expenses for the quarter were ¥42,212,732.60, compared to ¥39,093,474.01, an increase of 5.4%[25] Acquisitions and Investments - The company acquired 100% equity of Shanghai Hengling Pharmaceutical Technology Co., Ltd. in January 2024[15] - In March 2024, the company established NuoSiGe (Nanjing) Pharmaceutical Technology Co., Ltd. with a registered capital of 2 million RMB, holding 100%[15] - The company established an industry fund in collaboration with CICC Capital, which has completed registration and obtained the business license[17] Legal Matters - The company is involved in a legal dispute regarding a contract dispute with its actual controller and a subsidiary, with ongoing litigation updates[18] Other Financial Metrics - The company experienced a significant increase in goodwill, which rose by 102,005.36% due to the acquisition of a subsidiary[7] - The company reported a 384.23% increase in fair value changes in financial assets, totaling ¥9,443,052.07, attributed to an increase in the amount of financial products not yet matured[10] - The company’s cash and cash equivalents decreased by 30.31% to ¥690,986,044.89, primarily due to an increase in the balance of bank cash management products not yet matured[7] - The company’s accounts receivable increased from 89,996,806.71 RMB to 100,431,414.26 RMB during the reporting period[22] - The company’s deferred tax assets increased to ¥12,574,972.73 from ¥7,620,348.72, a growth of 65.5%[24] - The company incurred cash outflows from financing activities amounting to CNY 105.71 million, compared to CNY 15.02 million in the previous year, indicating a significant increase in cash outflows[28]